ImmunoVec
PrivateLast Round
Seed Round
Jun 29, 2026
Total Funding Raised
$56.55M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ImmunoVec is a biotechnology company developing a platform for in-vivo cell engineering to create therapies for autoimmune diseases, solid tumors, and genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts, Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoVec Comparables
Compare ImmunoVec with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alaya.bio | 84% | |
| AbbVie | 84% | |
| Cove Therapeutics, Inc. | 80% |
ImmunoVec Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 29, 2026 | ||||
| Series A | Oct 8, 2025 | ||||
| Grant | Oct 8, 2025 | ||||
| Grant | May 29, 2025 | ||||
| Seed | Mar 2, 2022 | ||||
Grant | Dec 2, 2021 |
ImmunoVec Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Constellar Ventures | Seed |
| California Institute for Regenerative Medicine | Grant |
| Anthem Venture Partners | Seed, Series A |
| ARPA-H | Grant |
| Onelin Capital Corporation | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 9, representing 69% of headcount.
- Jun 29, 2026
Raised $13M in seed funding.
ImmunoVec Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImmunoVec's valuation, stock price, and market status.
Is ImmunoVec a public or private company?
ImmunoVec is a private company.
What is the current stock price of ImmunoVec?
ImmunoVec is a private company, so its shares have no public market price. Caplight tracks ImmunoVec's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoVec worth (valuation)?
Valuation information for ImmunoVec is not publicly available.
Can I buy ImmunoVec stock?
ImmunoVec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoVec's last funding round?
ImmunoVec's most recent funding round was Seed Round on June 29, 2026.
Who are the main investors in ImmunoVec?
Key investors in ImmunoVec include Constellar Ventures, California Institute for Regenerative Medicine, Anthem Venture Partners, ARPA-H, Onelin Capital Corporation.
Will ImmunoVec IPO soon?
No public IPO plans have been announced for ImmunoVec.
How can I track ImmunoVec secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoVec's shares on secondary markets.